- Market Capitalization, $K 1,491,648
- Shares Outstanding, K 46,614
- Annual Sales, $ 77,060 K
- Annual Income, $ -135,670 K
- 60-Month Beta 1.21
- Price/Sales 19.40
- Price/Cash Flow N/A
- Price/Book 5.48
|Period||Period Low||Period High||Performance|
| || |
+3.58 (+12.60%)since 11/01/23
| || |
+5.56 (+21.03%)since 09/01/23
| || |
+13.72 (+75.05%)since 12/01/22
A mixed trial could hurt a kidney drug's chances of full approval.
Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of 16.67% and 3.32%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for first quarter 2023 and provided a business update.
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of -17.65% and 3.02%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...
VBI Vaccines, Inc. (VBIV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report first quarter 2023 financial results on Thursday, May 4, 2023. Mirum will also host a conference call to discuss the first...
IDEAYA Biosciences, Inc. (IDYA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength...
Mirum Pharmaceuticals, Inc. (“Mirum”) (Nasdaq: MIRM) today announced the pricing of its offering of $275.0 million aggregate principal amount of 4.00% convertible senior notes due 2029 (the “notes”)...
Stocks that traded heavily or had substantial price changes Wednesday: American Airlines, Emerson Electric fall; Triton, Chart rise
Mirum Pharmaceuticals, Inc. (“Mirum”) (Nasdaq: MIRM) today announced its intention to offer, subject to market and other conditions, $200.0 million aggregate principal amount of convertible senior...
|Mirum Pharmaceuticals Inc|
|DWA Healthcare Momentum Invesco ETF|
|Virtus Lifesci Biotech Products ETF|
|S&P Biotech SPDR|
|Raymond James Sb-1 Equity Invesco ETF|
|FT Active Factor Small Cap ETF|
|3rd Resistance Point||33.56|
|2nd Resistance Point||33.03|
|1st Resistance Point||32.51|
|1st Support Level||31.46|
|2nd Support Level||30.93|
|3rd Support Level||30.41|